Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
Feb 7 (Reuters) - Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.
(Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cardano and ADA Enthusiast Shares Update on the Altcoin, Is There Hope for the Bleak Start to 2026?
LiquidChain Joins the Altcoins to Buy Conversation: A New Layer Under Ethereum and Solana
Polygon price double bottoms as Tazapay, Revolut, Paxos, and Moonpay payments rise
Trump disclaims UAE World Liberty stake knowledge, Gemini exits, China bans yuan stablecoins | Weekly Recap
Trending news
MoreCrypto prices
More
